09/171697

(FILE 'HOME' ENTERED AT 12:47:18 ON 20 AUG 1999)

	FILE	'REGISTRY' ENTERED AT 12:47:26 ON 20 AUG 1999						
L1		STRUCTURE UPLOADED						
L2		0 S L1						
L3	STRUCTURE UPLOADED							
L4								
L5		23 S L3 SSS FULL						
	DII	LONDING LONDED BY 10.40.00 ov 00 pvg 1000						
L6	LIFF	'CAPLUS' ENTERED AT 12:49:29 ON 20 AUG 1999						
го		6 S L3						
	FILE	'BEILSTEIN' ENTERED AT 12:51:01 ON 20 AUG 1999						
L7		0 S L3						
L8		3 S L3 SSS FULL						
=>	d 13							
L3	HAS NO	ANSWERS						
L3		STR						

09/171697

ANSWER 1 OF 3 BEILSTEIN COPYRIGHT 1999 BEILSTEIN CD&S L8

6667400 Beilstein Beilstein Reg. No. (BRN): C19 H14 Cl I N2 O4 Molecular Formula (MF):

Autonom Name (AUN):

4-benzyloxycarbonylamino-5-chloro-7-iodo-quinoline-

2-carboxylic acid methyl ester

6-22 Beilstein Reference (SO): 496.69 Formula Weight (FW):

27817; 5228; 1762; 289 Lawson Number (LN):

Preparation:

PRE

Start: BRN=6647181 (3-chloro-5-iodo-phenylimino)-acetic acid methyl

ester, BRN=2557091 benzyl N-vinylcarbamate

boron trifluoride etherate Reag:

2.5 hour(s) Time: -5.0 - 20.0 Cel Temp:

ByProd: BRN=6667053 4-benzyloxycarbonylamino-7-chloro-5-iodo-quinoline-2-

carboxylic acid methyl ester

Reference(s):

1. Leeson, Paul D.; Carling, Robert W.; Moore, Kevin W.; Moseley, Angela M.; Smith, Julian D.; et al., J.Med.Chem., 35 <1992> 11, 1954-1968,

LA:

EN, CODEN: JMCMAR

Note(s):

2. Yield given. Yields of byproduct given. Title compound not separated from byproducts

=> d 2-3 ide pre

ANSWER 2 OF 3 BEILSTEIN COPYRIGHT 1999 BEILSTEIN CD&S L8

Beilstein Reg. No. (BRN): 6667053 Beilstein

Molecular Formula (MF): C19 H14 Cl I N2 O4

Autonom Name (AUN):


4-benzyloxycarbonylamino-7-chloro-5-iodo-quinoline-

2-carboxylic acid methyl ester

Beilstein Reference (SO): Formula Weight (FW): 6-22 496.69

Lawson Number (LN):

27817; 5228; 1762; 289



Preparation:

PRE

Start: BRN=6647181 (3-chloro-5-iodo-phenylimino)-acetic acid methyl

ester, BRN=2557091 benzyl N-vinylcarbamate

Reag: boron trifluoride etherate

Time: 2.5 hour(s)
Temp: -5.0 - 20.0 Cel

ByProd: BRN=6667400 4-benzyloxycarbonylamino-5-chloro-7-iodo-quinoline-2-

carboxylic acid methyl ester

Reference(s):

 Leeson, Paul D.; Carling, Robert W.; Moore, Kevin W.; Moseley, Angela M.; Smith, Julian D.; et al., J.Med.Chem., 35 <1992> 11, 1954-1968,

LA:

EN, CODEN: JMCMAR

Note(s):

2. Yield given. Yields of byproduct given. Title compound not separated from byproducts

L8 ANSWER 3 OF 3 BEILSTEIN COPYRIGHT 1999 BEILSTEIN CD&S

Beilstein Reg. No. (BRN): 206218 Beilstein Molecular Formula (MF): C12 H10 N2 O3

Chemical Name (CN): 4-acetylamino-quinoline-2-carboxylic acid

4-Acetylamino-chinolin-2-carbonsaeure

Autonom Name (AUN): 4-acetylamino-quinoline-2-carboxylic acid

Beilstein Reference (SO): 4-22-00-06818

Formula Weight (FW): 230.22

Lawson Number (LN): 27823; 1155

Preparation:

PRE

Start: BRN=24052 N-<2-trans(?)-styryl-<4>quinolyl>-acetamide

Reag: KMnO4, aqueous pyridine

Reference(s):

1. Royer, J.Chem.Soc., 1949 1803, 1806, CODEN: JCSOA9

Note(s):

2. Handbook Data

```
ANSWER 1 OF 6 CAPLUS COPYRIGHT 1999 ACS
L6
    1998:804187 CAPLUS
ΑN
DN
    130:47492
    Quinoline compounds, compositions and method suitable for amelioration of
ΤI
    withdrawal syndromes and withdrawal-induced brain damage
    Tabakoff, Boris; Snell, Lawrence; Hoffman, Paula L.
IN
    Lohocla Research Corp., USA
PΑ
     PCT Int. Appl., 63 pp.
SO
    CODEN: PIXXD2
DT
    Patent
    English
LΑ
FAN.CNT 1
                                         APPLICATION NO. DATE
                     KIND DATE
    PATENT NO.
                     ____
                                         _____
     ______
                                     WO 1998-US11312 19980605
    WO 9855125
                    A1 19981210
PΙ
        W: AU, CA, JP, MX, RU, US, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
        RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
            PT, SE
                                          US 1997-48848
                                                           19970606
                           19981221
                                          AU 1998-78088
                                                           19980605
    AU 9878088
                      A1
                                          US 1997-48848
                                                           19970606
                                          WO 1998-US11312 19980605
    MARPAT 130:47492
OS
    Quinoline compds., compns. and methods for ameliorating alc. or drug
AΒ
     dependency withdrawal syndromes and withdrawal-induced brain damage are
     disclosed. In particular, a series of
N-substituted-4-ureido-5,7-dihalo-2-
     carboxy quinoline compds. are disclosed having combined properties as
     antagonists of voltage-sensitive sodium channels (VSNaC) and as selective
     competitive antagonists at the strychnine-intensive glycine site of
     N-methyl-D-aspartate (NMDA) receptors. The disclosed compds. prevent or
     reduce the signs and symptoms of neurohyperexcitability and particularly
     the neurohyperexcitability assocd. with withdrawal syndrome manifested by
     patients upon withdrawal from chronic use of dependence inducing agents
     (e.g, ethanol, barbiturates, opiates etc.). The combined actions of the
     disclosed compds. on VSNaC and NMDA receptors also impart properties to
     these compds. that are important in preventing and reducing excitotoxic
     neurodegeneration and reducing anxiety without the undesirable CNS
     depressant side-effects of agents hitherto employed for these purposes.
     210692-60-7P
     RL: BAC (Biological activity or effector, except adverse); RCT
(Reactant);
     SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological
     study); PREP (Preparation); USES (Uses)
        (quinoline compds. for amelioration of alc. and drug withdrawal
        syndromes and withdrawal-induced brain damage)
RN
     210692-60-7 CAPLUS
     2-Quinolinecarboxylic acid,
5,7-dichloro-4-[[(diphenylamino)carbonyl]amino
     ]-, methyl ester (9CI) (CA INDEX NAME)
```

IT 210692-58-3P 217170-45-1P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(quinoline compds. for amelioration of alc. and drug withdrawal syndromes and withdrawal-induced brain damage)

RN 210692-58-3 CAPLUS

CN 2-Quinolinecarboxylic acid,

5,7-dichloro-4-[[(diphenylamino)carbonyl]amino]- (9CI) (CA INDEX NAME)

RN 217170-45-1 CAPLUS

CN 2-Quinolinecarboxylic acid, 5,7-dichloro-4-[[[(2-methoxyphenyl)phenylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)

L6 ANSWER 2 OF 6 CAPLUS COPYRIGHT 1999 ACS

AN 1998:493263 CAPLUS

DN 129:131259

TI 4-Urea-5,7-dichlorokynurenic acid derivative anticonvulsants, and preparation thereof

IN Nichols, Alfred C.; Yielding, K. Lemone

PA USA

SO U.S., 9 pp. CODEN: USXXAM

DT Patent

LA English

FAN.	CNT 1 PATENT NO.	KIND		APPLICATION NO.	DATE				
PI	US 5783700 US 5914403	A	19980721	US 1997-887627 US 1998-103963 US 1997-887627	19980624				
os AB of	MARPAT 129:131259 Coupled to the N-methyl-D-aspartate (NMDA) receptor complex is a strychnine-insensitive binding site for glycine. Pharmacol. antagonism								
	glycine at this site may produce anticonvulsant activity. Twelve 4-urea-5,7-dichlorokynurenic acid derivs. were synthesized and subsequently screened in mice for anticonvulsant activity using MES, Met and TTE tests, and a rotorod test was used to det. neurotoxicity. Seven of the derivs. had anticonvulsant activity in TTE testing at 100 mg/kg. One deriv. had an ED50 value of 134 mg/kg in TTE testing. Two derivs. MES activity. Only one deriv. was neurotoxic in the rotorod test. Compds. were screened at a 10 uM concn. for activity in displacing 5,7-dichlorokynurenic acid from synaptosomal membrane fragments. Nine o the twelve compds. synthesized and tested have demonstrated								
the	activity. Thus, compds. of the present invention should be usable for								
the	treatment of epilepsy, neurodegenerative diseases, and other syndromes involving inhibition or excessive stimulation of the NMDA receptor complex.								
ΙΤ	210692-49-2P 210692-50-5P 210692-51-6P 210692-52-7P 210692-54-9P 210692-55-0P 210692-56-1P 210692-57-2P 210692-58-3P 210692-60-7P 210692-61-8P 210692-62-9P RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)								
RN	(urea-dichlorokynurenate deriv. anticonvulsants, and prepn. thereof) 210692-49-2 CAPLUS								
CN 5,7-	2-Quinolinecarboxylic acid, -dichloro-4-[[(diethylamino)carbonyl]amino]-								

RN 210692-50-5 CAPLUS CN 2-Quinolinecarboxylic acid, 5,7-dichloro-4-[[(diethylamino)carbonyl]amino], ethyl ester (9CI) (CA INDEX NAME)

RN 210692-51-6 CAPLUS
CN 2-Quinolinecarboxylic acid,
5,7-dichloro-4-[[(diethylamino)carbonyl]amino](9CI) (CA INDEX NAME)

RN 210692-54-9 CAPLUS
CN 2-Quinolinecarboxylic acid,
5,7-dichloro-4-[[(dimethylamino)carbonyl]amino
]- (9CI) (CA INDEX NAME)

RN 210692-55-0 CAPLUS
CN 2-Quinolinecarboxylic acid,
5,7-dichloro-4-[[(dibutylamino)carbonyl]amino] , ethyl ester (9CI) (CA INDEX NAME)

RN 210692-61-8 CAPLUS

CN 2-Quinolinecarboxylic acid, 5,7-dichloro-4-[[[(3methoxyphenyl)phenylamino]carbonyl]amino]-, ethyl ester (9CI) (CA INDEX
NAME)

RN 210692-62-9 CAPLUS

CN 2-Quinolinecarboxylic acid, 5,7-dichloro-4-[[[(3-methoxyphenyl)phenylamino]carbonyl]amino]- (9CI) (CA INDEX NAME)

L6 ANSWER 3 OF 6 CAPLUS COPYRIGHT 1999 ACS.

AN 1997:686837 CAPLUS

DN 128:3594

TI A series of quinoline-2-carboxylic acid derivatives: new potent glycine site NMDA receptor antagonists

AU Kim, Ran Hee; Choi, Jin Li; Choi, Seung Won; Lee, Kwang Sook; Jung, Young Sik; Park, Woo Kyu; Seong, Churl Min; Park, No Sang

Korea Research Institute of Chemical Technology, Taejeon, 305-606, S. CS Korea

Bull. Korean Chem. Soc. (1997), 18(9), 939-945 so

CODEN: BKCSDE; ISSN: 0253-2964

Korean Chemical Society PB

Journal DT

LA English

GT

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Several types of 4-substituted-quinoline-2-carboxylic acid derivs. AB possessing different substituents at C4-position such as sulfonyl, phosphonyl, carbonyl groups, or a flexible alkyl chain have been synthesized and evaluated for their in vitro antagonistic activity at the glycine site on the N-methyl-D-aspartate (NMDA) receptor. Of them, $\overline{5}, \overline{7}$ -dichloro-4-(tolylsulfonylamino)-quinoline-2-carboxylic acid was found to have the best in vitro binding affinity with IC50 of 0.57 .mu.M. On the other hand, in quinolinecarboxylic acids I and II (n = 1, 2) the introduction of flexible alkyl chains on C4 of the quinoline mother nuclei

caused a significant decrease of the in vitro binding affinity. In addn.,

replacement of polar carboxylic acid group on C2 by neutral bioisosteres in quinolinic amides III (R = NHCH2CH2CO2H, Q, Q1, Q2) also seems to be disadvantageous to in vitro activity. In the structure-activity relationship (SAR) study of the 4-substituted quinoline-2-carboxylic acid acid derivs., it was realized that the substitution pattern on C4 significantly influences on the binding affinity for the glycine site of NMDA receptor and the binding affinity might be increased by the introduction of a suitable electron rich substituent at C4 which has the ability of H-bonding donor.

198696-81-0P 198696-83-2P ΙT

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (prepn. and NMDA receptor antagonist activity of quinolinecarboxylic acid derivs.)

198696-81-0 CAPLUS RN

2-Quinolinecarboxylic acid,

5,7-dichloro-4-[[(diethoxyphosphinyl)acetyl]am

ino]- (9CI) (CA INDEX NAME)

198696-83-2 CAPLUS RN

2-Quinolinecarboxylic acid, 4-(benzoylamino)-5,7-dichloro- (9CI) (CA CN INDEX NAME)

IT 198696-79-6P 198696-80-9P 198696-82-1P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation)
 (prepn. and NMDA receptor antagonist activity of quinolinecarboxylic
 acid derivs.)

RN 198696-79-6 CAPLUS

CN 2-Quinolinecarboxylic acid, 5,7-dichloro-4-[(chloroacetyl)amino]-, methyl ester (9CI) (CA INDEX NAME)

RN 198696-80-9 CAPLUS

CN 2-Quinolinecarboxylic acid,

5,7-dichloro-4-[[(diethoxyphosphinyl)acetyl]am ino]-, methyl ester (9CI) (CA INDEX NAME)

RN 198696-82-1 CAPLUS

CN 2-Quinolinecarboxylic acid, 4-(benzoylamino)-5,7-dichloro-, methyl ester (9CI) (CA INDEX NAME)

L6 ANSWER 4 OF 6 CAPLUS COPYRIGHT 1999 ACS

AN 1994:605226 CAPLUS

DN 121:205226

TI Aminoquinolinecarboxylates and aminoquinolinecarboxamides as

anticonvulsive agents Nichols, Alfred C.; Yielding, K. Lemone IN Board of Regents, University of Texas System, USA PA SO PCT Int. Appl., 55 pp. CODEN: PIXXD2 DТ Patent LΑ English FAN.CNT 1 PATENT NO. KIND DATE APPLICATION NO. DATE ______ ____ -----_____ _____ A1 WO 1994-US128 WO 9417042 19940804 19940104 PΤ W: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SK, UA, UZ, VN RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG US 1993-6918 19930122 19960220 US 1993-6918 US 5493027 Α 19930122 19940815 AU 1994-61209 19940104 AU 9461209 A1 US 1993-6918 19930122 WO 1994-US128 19940104

MARPAT 121:205226 os

GΙ

Anticonvulsant 4-amino-2-quinolinecarboxylates and 4-amino-2-AΒ quinolinecarboxamides I (R2-R4 = H, alkyl; R5 = H, halo; R7 = halo; R8 = H, Me; X = oxygen, nitrogen) were disclosed. Coupled to the NMDA receptor

channel complex is a strychnine-insensitive binding site for glycine; pharmacol. antagonism of this site can produce anticonvulsant activity. Derivs. of kynurenic acid, pyridine and indolecarboxylates were evaluated as antagonists for glycine binding and as anticonvulsants.

157848-07-2 TΨ

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses) (anticonvulsant)

157848-07-2 CAPLUS RN

2-Quinolinecarboxylic acid, 5,7-dichloro-4-[(1-oxobutyl)amino]- (9CI) CN

(CA

INDEX NAME)

ANSWER 5 OF 6 CAPLUS COPYRIGHT 1999 ACS L6

1994:605125 CAPLUS ΑN

121:205125 DN

```
TI
     Preparation of
[[(carboxyheterocyclyl)carbamoyl]pyrrolidinylthio]carbapene
     ms as antibiotics
ΙN
     Jung, Frederic Henri; Arnould, Jean Claude
PΑ
     Zeneca Ltd., UK; Zeneca Pharma S.A.
SO
     Eur. Pat. Appl., 27 pp.
     CODEN: EPXXDW
DT
     Patent
LA
     English
FAN.CNT 1
     PATENT NO.
                     KIND DATE
                                           APPLICATION NO.
                                                            DATE
                                           _____
                            -----
     -----
                      ____
ΡI
    EP 581500
                      A1
                            19940202
                                           EP 1993-305607
                                                            19930716
     EP 581500
                     В1
                           19980909
        R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT,
SE
                                           EP 1992-402105
                                                            19920721
    CA 2099818
                       AΑ
                            19940122
                                           CA 1993-2099818
                                                            19930705
                                           EP 1992-402105
                                                            19920721
    AT 170859
                       Ε
                            19980915
                                           AT 1993-305607
                                                            19930716
                                           EP 1992-402105
                                                            19920721
    ES 2121585
                       Т3
                            19981201
                                           ES 1993-305607
                                                            19930716
                                           EP 1992-402105
                                                            19920721
     JP 06179674
                       A2
                            19940628
                                           JP 1993-177903
                                                            19930719
                                           EP 1992-402105
                                                            19920721
     US 5441949
                            19950815
                                           US 1994-307048
                       A
                                                            19940916
                                           EP 1992-402105
                                                            19920721
                                           US 1993-86836
                                                            19930707
OS
    MARPAT 121:205125
```

Title compds. [I; R1 = MeCH(OH), MeCHF, CH2OH; R2,R3 = H, alkyl; Z = (iso)quinolinediyl, quinazolinediyl, quinoxalinediyl, etc.] were prepd. Thus, disodium (1R,5S,6S,8R,2'S,4'S)-2-[2-(8-carboxyquinol-6-ylcarbamoyl)pyrrolidin-4-ylthio]-6-(1-hydroxyethyl)-1-methylcarbapenem-3-carboxylate, prepd. in 5 steps from 6-amino-8-carboxyquinoline (prepn. given), had MIC of 0.13 and 0.03.mu.g/mL against Staphylococcus aureus Oxford and Escherichia coli DCO, resp.

Ι

IT 157915-26-9P 157915-27-0P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. and reaction of, in prepn. of antibiotic)

RN 157915-26-9 CAPLUS

CN 2-Quinolinecarboxylic acid, 4-[[[4-(acetylthio)-1-[[(4-nitrophenyl)methoxy]carbonyl]-2-pyrrolidinyl]carbonyl]amino]-, 2-propenyl ester, (2S-cis)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

RN 157915-27-0 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 6-(1-hydroxyethyl)-4-methyl-7-oxo-3-[[1-[[(4-nitrophenyl)methoxy]carbonyl]-5-[[[2-[(2-propenyloxy)carbonyl]-4-quinolinyl]amino]carbonyl]-3-pyrrolidinyl]thio]-, 2-propenyl ester, [4R-[3(2S*,4S*),4.alpha.,5.beta.,6.beta.(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

IT 157914-94-8P

RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation) (prepn. of, as antibiotic)

RN 157914-94-8 CAPLUS

CN 1-Azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid, 3-[[5-[[(2-carboxy-4-quinolinyl)amino]carbonyl]-3-pyrrolidinyl]thio]-6-(1-hydroxyethyl)-4-methyl-7-oxo-, [4R-[3(2S*,4S*),4.alpha.,5.beta.,6.beta.(R*)]]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

- L6 ANSWER 6 OF 6 CAPLUS COPYRIGHT 1999 ACS
- AN 1991:449667 CAPLUS
- DN 115:49667
- TI Preparation of quinolines and thienopyridines as excitatory amino acid antagonists
- . IN Harrison, Boyd L.; Baron, Bruce M.
 - PA Merrell Dow Pharmaceuticals (Canada) Inc., Can.
 - SO Can. Pat. Appl., 53 pp.

FI 95795 ·

С

19960325

US 1989-352423

19890516

CODEN: CPXXEB

DT Patent

LA English

	~	jlish							*
FAN.	PAT	ZENT NO.		KIND	DATE		API	PLICATION NO.	DATE
PI		2016908			19901116		CA US	1990-2016908 1989-352423 1990-496748	19890516
	US	5026700		A	19910625		US	1990-496748 1989-352423	19900321
					19920512		US US US	1991-654997 1989-352423 1990-496748	19910214 19890516 19900321
		PAMILY IN	FORMAT	'ION:					
FAN	FAN 1991:185467 PATENT NO.						PLICATION NO.	DATE	
ΡI								1990-109226	
	ΕP	398283		B1	19941102				
		R: AT,	BE, C	H, DE	, DK, ES,	FR,	GB, C	GR, IT, LI, LU	J, NL, SE
					,		US	1989-352423	19890516
	ΑU	9054914		A1	19901122		AU	1989-352423 1990-54914	19900510
	AU	626418		B2	19920730				
							US	1989-352423	19890516
	zA	9003588		A	19910227			1990-3588	
							US	1989-352423	19890516
	HU	54657		A2	19910328		HU	1990-3031	19900514
	HU	214322		В	19980302				
							US	1989-352423	19890516
	IL	94377		A1	19970110		IL	1990-94377	19900514
							US	1989-352423	19890516
	NO	9002179		A	19901119		ИО	1990-2179	19900515
	NO	177141		В	19950418				
	NO	177141		С	19950726				
							US	1989-352423	
	CN	1047292		A	19901128		CN	1990-103522	19900515
	CN	1027369		В	19950111				
							US	1989-352423	19890516
	JР	03011067		A2	19910118		JP	1990-123258	19900515
								1989-352423	
	FI	95795		В	19951215		FI	1990-2416	19900515

OS MARPAT 115:49667

GΙ

$$Q^{1}=$$
 $Q^{2}=$
 Q^{2

Ι

The title compds. I and II, etc., were prepd. For I, II, X = O, S, NH; n = integer; R1, R2 = NR3R4, OH, OR5, etc.; R3, R4 = H, alkyl; R5 = alkyl, (substituted) Ph, etc.; D = H, alkyl; A = Q1, Q2, etc.; R = H, OH, CN, NO2, etc. I and II, are excitatory amino acid antagonists (no data). Treatment of kynurenic acid with NaH and then BrCH2CO2Et, sapon., and workup, gave quinoline III.

IT 134883-37-7P

RL: SPN (Synthetic preparation); PREP (Preparation) (prepn. of, as excitatory amino acid antagonist)

RN 134883-37-7 CAPLUS

CN 2-Quinolinecarboxylic acid, 5,7-dichloro-4-[[[2-(diethylamino)ethoxy]carbonyl]amino]-, 2-(diethylamino)ethyl ester (9CI) (CA INDEX NAME)

=> file beil

SINCE FILE TOTAL COST IN U.S. DOLLARS ENTRY SESSION FULL ESTIMATED COST 28.34 149.39 SINCE FILE TOTAL DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SESSION ENTRY -3.21CA SUBSCRIBER PRICE -3.21

FILE 'BEILSTEIN' ENTERED AT 12:51:01 ON 20 AUG 1999 COPYRIGHT (c) 1999 Beilstein Chemiedaten und Software GmbH, Beilstein Institut fuer Literatur der organischen Chemie

FILE LAST UPDATED: 9 JUN 1999

FILE COVERS 1779 TO 1999.

=> s 13

SAMPLE SEARCH INITIATED 12:51:11 FILE 'BEILSTEIN'
SAMPLE SCREEN SEARCH COMPLETED - 2 TO ITERATE
100.0% PROCESSED 2 ITERATIONS
SEARCH TIME: 00.00.02

0 ANSWERS

pct/us98/11312

(FILE 'HOME' ENTERED AT 19:17:01 ON 21 JUL 1998)

```
FILE 'REGISTRY' ENTERED AT 19:17:07 ON 21 JUL 1998
```

L1 STRUCTURE UPLOADED

L2 0 S L1

L3 STRUCTURE UPLOADED

L4 0 S L3

L5 STRUCTURE UPLOADED

L6 0 S L5

L7 1 S L5 SSS FULL

FILE 'MARPAT' ENTERED AT 19:20:31 ON 21 JUL 1998

L8 0 S L1

L9 0 S L3

L10 0 S L3 SSS FULL

L11 6 S L5 SSS FULL

FILE 'CAPLUS' ENTERED AT 19:23:57 ON 21 JUL 1998

L12 6 S L11

L13 1 S L7

L14 7 S L12 OR L13

=> d 11

L1 HAS NO ANSWERS

L1 STR

Structure attributes must be viewed using STN Express query preparation.

=> d 13

L3 HAS NO ANSWERS

L3 STR

Structure attributes must be viewed using STN Express query preparation.

=> d 15

L5 HAS NO ANSWERS

L5 STR

Structure attributes must be viewed using STN Express query preparation.

=> d 1-7 bib abs

L14 ANSWER 1 OF 7 CAPLUS COPYRIGHT 1998 ACS

AN 1997:798024 CAPLUS

DN 128:81939

TI Phosphors and electron transport materials in electroluminescent device elements

IN Kido, Junji; Fukuoka, Naohiko; Takeda, Takashi

PA Chemipro Kasei K. K., Japan

SO Jpn. Kokai Tokkyo Koho, 35 pp.

CODEN: JKXXAF

PI JP 09316441 A2 971209 Heisei

AI JP 96-257464 960906

PRAI JP 96-96249 960326

DT Patent

LA Japanese

OS MARPAT 128:81939

GI

- AB The elements comprise a metal complex of 8-hydroxyquinoline deriv. ligands I or II (R1-12 = H, alkyl, halo-alkyl, dialkyl amino, diarylamino, CN, halo, (substituted) aryl; .gtoreq.1 selected from R4-9 takes R12=R10R11; R1,2, R2,3, R1-3 may form condensed ring).
- L14 ANSWER 2 OF 7 CAPLUS COPYRIGHT 1998 ACS

Ι

- AN 1997:574809 CAPLUS
- DN 127:248873
- TI Energy beam-sensitive acid generators with no toxicity or odor and good solubility, and compositions, curable compositions, and cured products using the same
- IN Toba, Yasumasa; Tanaka, Yasuhiro; Yasuike, Madoka

Ι

- PA Toyo Ink Mfg. Co., Ltd., Japan
- SO Jpn. Kokai Tokkyo Koho, 59 pp.
 - CODEN: JKXXAF
- PI JP 09221652 A2 970826 Heisei
- AI JP 96-30196 960219
- DT Patent
- LA Japanese
- OS MARPAT 127:248873

GΙ

- AB The title compns. contain I (R = alkyl, alkenyl, aryl, etc.; R1 = benzyl, phenacyl, allyl, etc.; j = 0-4; k = 0-3; Y = F, Cl; Z = Ph substituted by .gtoreq.2 electron-withdrawing groups chosen from F, cyano, nitro, and CF3). A mixt. of 100 parts ERL-4221 and 1 part N-benzylquinolinium tetrakis(pentafluorophenyl)borate in an Al cup was irradiated with 500 mW high-pressure Hg lamp through a thermal ray-cutting filter at 10 cm for 5 min showing cured product on the bottom.
- L14 ANSWER 3 OF 7 CAPLUS COPYRIGHT 1998 ACS
- AN 1996:672638 CAPLUS
- DN 125:300832
- TI Amination process and catalysts for producing aminonitropyridines from nitropyridines and O-protected hydroxylamines
- IN Seko, Shinzo; Miyake, Kunihito
- PA Sumitomo Chemical Company Limited, Japan
- SO Eur. Pat. Appl., 18 pp.
 - CODEN: EPXXDW

The title compds. [I; R4 = H, alkyl, cycloalkyl, aralkyl group; X1-X3 = H, halogen, NO2, CN, aryl group, arom. heterocycle, (un)substituted alkyl group, etc.; Y = O; n = 0, 1], useful as intermediates, are prepd. in high yield and selectivity by the amination of a nitropyridine (II) with an O-substituted hydroxylamine R4HNOR5 (R5 = alkyl group or an aralkyl) in the presence of a base and a metal catalyst. Thus, 6-methoxy-3-nitropyridine was aminated with H2NOMe in the presence of KOCMe3 and ZnC12, producing 2-amino-6-methoxy-3-nitropyridine in 87% yield.

L14 ANSWER 4 OF 7 CAPLUS COPYRIGHT 1998 ACS

AN 1994:8598 CAPLUS

DN 120:8598

TI 1-Acyloxy-2-azolylethanes and their preparation and use as fungicides

IN Jautelat, Manfred; Dutzmann, Stefan

PA Bayer A.-G., Germany

SO Ger. Offen., 15 pp.

CODEN: GWXXBX

PI DE 4205081 A1 930826

AI DE 92-4205081 920220

DT Patent

LA German

OS MARPAT 120:8598

GΙ

AB Title compds. I [R1 = (un) substituted alkyl, alkenyl, or cycloalkyl; R2 = (un) substituted alkyl, alkenyl, cycloalkyl, aryl, aralkyl, or heteroaryl; Y = N, CH] (12 examples) were prepd. as fungicides. Thus, substitution reaction of 1,2,4-triazole with

1-chlorocyclopropyl chloromethyl ketone (51%), redn. of the keto group with NaBH4 (90%), and esterification of the resultant alc. with 2-chlorobenzoyl chloride (97%) gave title compd. II. In tests against Erysiphe graminis f. sp. hordei on barley, II at 2.5 ppm (spray) was superior to 3 known comparison compds. of structure I [R1 = 2,4-dichlorophenyl, R2 = CMe3, Y = N (free base and HNO3 salt); or R2 = Me, others same].

L14 ANSWER 5 OF 7 CAPLUS COPYRIGHT 1998 ACS

AN 1993:560613 CAPLUS

DN 119:160613

TI Preparation of 2-substituted quinolines for treating leishmaniasis

IN Fournet, Alain; Angelo Barrios, Alcira; Munoz, Victoria; Hocquemiller, Reynald; Roblot, Francois; Bruneton, Jean; Richomme, Pascal; Gantier, Jean Charles

PA Institut Français de Recherche Scientifique pour le Developpement en Cooperation (ORSTOM), Fr.

so PCT Int. Appl., 38 pp.

CODEN: PIXXD2

PI WO 9307125 A1 930415

DS W: BR, JP, US

RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG

AI WO 92-FR903 920929

PRAI FR 91-12174 911003

DT Patent

LA French

os MARPAT 119:160613

GΙ

$$R^{5}$$
 R^{6}
 R^{7}
 R^{1}
 R^{3}
 R^{2}

Title compds. I [R1, R3-R7 each independently represent H, linear or branched C1-7 alkyl, alkenyl, epoxyalkyl, or mono- or polyalc., amine or amide, OR (R = H, C1-7 alkyl or alkenyl, Ph); R2 = OR (R as defined above), C1-7 alkyl, alkenyl, or epoxyalkyl, Ph, phenol, methylenedioxyphenyl, dimethoxyphenyl, or a C1-7 alkyl, alkenyl or epoxyalkyl group comprising at least one of the following substituents: a C1-4 alkyl or alkenyl, a Ph, phenol, dimethylphenyl, dimethoxyphenyl, or methylenedioxyphenyl, or OR' (R' = H, C1-4 alkyl or alkenyl, NHR'' (R'' = H, C1-4 alkyl or alkenyl), amide; or R2R3 form a furan ring] and their salts and derivs. thereof, are prepd. I are used as drugs, esp. for the treatment of leishmaniasis.

L14 ANSWER 6 OF 7 CAPLUS COPYRIGHT 1998 ACS

Ι

AN 1993:452681 CAPLUS

DN 119:52681

TI Two-cycle lubricants and methods of using them

IN Blythe, Glen H.

PA Lubrizol Corp., USA

SO PCT Int. Appl., 69 pp.

CODEN: PIXXD2
PI WO 9303120 A1 930218

DS W: AU, BR, CA, FI, JP, NO

RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE

WO 92-US6040 920721 PRAI US 91-744618 910809

! DT Patent

LΑ English

MARPAT 119:52681 OS

AB A fuel-lubricant mixt. for two-cycle internal-combustion engines comprises a major amt. of a fuel and a minor amt. sufficient to increase compression or release stuck piston rings, of a lubricant compn. comprising (A) .gtoreq.1 dispersant, (B) .gtoreq.1 reaction product of a fatty acid and a polyamine, optionally treated with an alkylene oxide, (C) .gtoreq.1 varnish dissolver selected from (1) keto alcs., (2) C.ltoreq.24 carboxylic esters, and (3) alkoxy alcs., and (D) .ltorsim.15 wt.% of the compn. of .gtoreq.1 fluidizing oil. The compn. also improves general engine cleanliness of two-cycle engines.

L14 ANSWER 7 OF 7 CAPLUS COPYRIGHT 1998 ACS

1978:507587 CAPLUS ΑN

DN 89:107587

Photocatalytic systems. Part II. Light absorption and constitution TIof heterocyclic 1,2-enediols

ΑU Weissenfels, M.; Punkt, J.

Sekt. Chem., Karl Marx Univ., Leipzig, E. Ger. Tetrahedron (1978), 34(3), 311-16 CS

SO CODEN: TETRAB; ISSN: 0040-4020

DTJournal

German LΑ

PPP MO calcns. showed that the chromophore of heterocyclic AΒ 1,2-enediols consists of a sym. arrangement of the hydroxyl acceptor and heterocyclic donor groups around the central double bond. The bathochromic shift of the longest wavelength .pi.-.pi.* transition depends on nonbonded interactions. The effect of substituents, and of intramol. chelation, on the electronic spectra of these enediols, was examd.

pct/us98/11312

L7 1 ANSWERS REGISTRY COPYRIGHT 1998 ACS

IN 1,2-Ethenediol, 1,2-bis(4-azido-2-quinolinyl)-, (E)- (9CI)

MF C20 H12 N8 O2

. . .

Double bond geometry as shown.

ALL ANSWERS HAVE BEEN SCANNED

=> file marpat

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 115.42 115.57

FULL ESTIMATED COST

FILE 'MARPAT' ENTERED AT 19:20:31 ON 21 JUL 1998
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 1998 American Chemical Society (ACS)

FILE CONTENT: 1988-PRESENT (VOL 104 ISS 14-VOL 128 ISS 26) (980712/ED)